Alembic Pharmaceuticals share news, announcements and annual reports
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Alembic Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹803.00up ₹5.15 (0.65%)BSE ₹801.20
Share price at the NSE close on 2 Nov 2026. Previous close ₹797.85.
2 Nov: open ₹801.10, high ₹806.70, low ₹786.50
52-week range of traded prices to 2 Nov 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,784 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.84
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.78
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 97,13548.0% delivered
Alembic Pharmaceuticals share news and announcements
971 announcements, routine notices left out, newest first. Page 19 of 20.
Apr 2015
27 Apr · Dividend
Board of Directors of the Company at its meeting held on April 27, 2015 has recommended a dividend of Rs. 3.50 (175%) per Equity Share of face value of Rs. 2 each, subject to approval of Shareholders at the ensuing Annual General Meeting.9 Apr · Board meeting
Inter alia, to transact following business: (1). To consider and approve Audited Financial Results of the Company for the Financial year ended March 31, 2015 (2). To consider and recommend dividend on Equity Shares, if any, for the Financial Year ended March 31, 2015.
Feb 2015
4 Feb · Management
Board of Directors of the Company at its meeting held on February 04, 2015 has appointed Dr. (Ms.) Archana Hingorani as an Additional Director (Independent Director) of the Company.
Jan 2015
Oct 2014
Sep 2014
24 Sep · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended September 30, 2014. The trading window shall remain closed from October 17, 2014 to October 21, 2014 for the above purpose.
Aug 2014
8 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2014
28 Jul · Board meeting
Board of Directors of the company at its meeting held on July 28, 2014 has inter alia taken following decisions : (1) Designation of Mr. R. K. Baheti, Director-Finance & Company Secretary of the Company as Director-Finance & Chief Financial Officer of the Company w.e.f. July 28, 2014 (2) Designation of Mr. Ajay Kumar Desai, Associate Vice President-Finance of the Company as Associate Vice President-Finance & Company Secretary and Compliance Officer of the Company w.e.f. July 28, 2014 .
Jun 2014
20 Jun · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended June 30, 2014.Further, the trading window shall remain closed from July 25, 2014 to July 29, 2014 for the above purpose.3 Jun · Meeting
Company has fixed Book Closure from July 21, 2014 to July 28, 2014 (both days inclusive) for the purpose of Annual General Meeting to be held on July 28, 2014 and payment of Dividend for the F.Y. 2013-14.
Apr 2014
28 Apr · Dividend
Board of Directors of the Company at its meeting held on April 28, 2014 has recommended a dividend of Rs. 3.00(150%) per Equity Share of Re. 2 each, subject to approval of Shareholders at the Annual General Meeting.
Jan 2014
Dec 2013
Oct 2013
9 Oct · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on October 30, 2013 inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended on September 30, 2013. The Company has now informed the Exchange that the aforesaid Board Meeting has been rescheduled and will now be held on October 25, 2013.Not held on this date
1 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended on September 30, 2013.
Aug 2013
8 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2013
9 Jul · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended June 30, 2013.
Jun 2013
5 Jun · Meeting
Register of Members and Share Transfer Books of the Company shall remain closed from July 31, 2013 to August 7, 2013 (both days inclusive) for the purpose of Annual General Meeting to be held on August 07, 2013 and payment of Dividend for the F.Y. 2012-13.
May 2013
2 May · Management
Board of Directors of the Company at its meeting held on May 02, 2013 has appointed Mr. Shaunak Amin as Additional Director and Director & President-Branded Formulations Business w.e.f. May 02, 2013.2 May · Dividend
Board of Directors of the Company at its meeting held on May 02, 2013 has recommended a dividend of Rs. 2.50 (125%) per Equity Share of Re. 2 each, subject to approval of Shareholders at the Annual General Meeting.
Mar 2013
15 Mar · Board meeting
Inter alia, to transact following business : (1) To consider and approve Audited Financial statements of the Company for the Financial year ended March 31, 2013; (2) To consider and recommend dividend for the Financial Year ended March 31, 2013.
Jan 2013
Dec 2012
18 Dec · Board meeting
Inter alia, to consider and approve the Un-audited Financial Results of the Company for the quarter ended on December 31, 2012.
Oct 2012
5 Oct · Board meeting
Inter alia, to consider and approve the Un-audited Financial Results of the Company for the quarter ended on September 30, 2012.